How can Pfenex’s platform technology enable the improvement and/or development of protein based therapeutics and vaccines?
The institutional knowledge possessed by the Pfenex scientific team which has been accumulated over the past 17 years and over 60 collaborations, including with 12 of the 15 top pharmaceutical companies in the world, is leveraged on every product development program we embark upon.
The comprehensive capability of Pfenex including the production platform, analytical capability and pilot scale production facility as well as our experienced scientific team will be leveraged on our partnered programs.
Pfenex is seeking co-development partnerships wherein our technology platform is uniquely enabling. The Pfenex platform has routinely demonstrated success in producing a broad range of highly complex proteins where legacy platforms have failed.
Become a Pfenex Partner
Submit the form below to request more information about becoming a Pfenex partner and a member of our team will get in touch promptly.
Our Current Partners
Pfenex is collaborating with Jazz to develop and commercialize multiple early stage hematology product candidates.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs.
The Biomedical Advanced Research and Development Authority
Supported by a $143.5MM advanced development contract Pfenex is collaborating with BARDA on the development of two novel anthrax vaccine candidates.
The Biomedical Advanced Research and Development Authority (BARDA) is established within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.
The National Institute of Allergy and Infectious Diseases
Pfenex previously worked the NIAID’s Division of Microbial and Infectious Diseases (DMID) to develop a P. falciparum Circumsporozoite (CSP) based malaria vaccine candidate. The product is currently in the preclinical stage.
The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.
Serum Institute of India Pvt. Ltd
Pfenex and Serum Institute of India Limited currently have a commercial license agreement for Pfenex Expression Technology. Under the agreement, which encompasses the use of the protein in future combination vaccine products, Serum Institute of India Limited will have a license to use Pfenex Expression Technology™ for the development and manufacture of vaccines at affordable prices across the globe. Serum currently has two products in human clinical studies that are subject to the license agreement.
Serum Institute of India Pvt. Ltd. is now the world’s largest vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. Vaccines manufactured by the Serum Institute are accredited by the World Health Organization, Geneva and are being used in around 140 countries across the globe in their national immunization programs, saving millions of lives throughout the world.
Merck & Co, Inc.
Pfenex and Merck & Co., Inc. currently have a multi-product commercial license agreement for Pfenex Expression Technology. The first product under the agreement is a proprietary protein vaccine component for which a high yield production strain and a fully-scalable fermentation process were successfully developed in less than six months. The process was subsequently transferred to Merck.
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases.